Europe is one of the largest and most demanding markets in the world for herbal medicines, and any botanical extract intended for pharmaceutical use must clear a strict set of regulatory hurdles before it can be placed on the market. For manufacturers and suppliers, understanding these requirements is not optional paperwork — it is the foundation of a successful market entry. This article explains the key regulatory requirements for botanical extracts for pharmaceuticals in Europe, from the legal framework to the quality standards that apply at every stage of the supply chain.

The legal framework: Directive 2001/83/EC and the Herbal Directive

The cornerstone of European pharmaceutical regulation is Directive 2001/83/EC, the Community code relating to medicinal products for human use. In 2004, Directive 2004/24/EC — commonly known as the Herbal Directive — amended this framework and introduced a simplified registration procedure specifically for traditional herbal medicinal products. Together, these directives govern how herbal medicinal products, including botanical extracts used as active substances, are authorised and marketed across the 27 EU member states. The system is designed to protect public health while securing the free movement of herbal medicines within the EU.

Three regulatory pathways for bringing a product to market

Companies seeking to bring a herbal medicinal product to market in the EU can choose between three main pathways, depending on the evidence available for the product:

1. Traditional use registration (Article 16a(1) of Directive 2001/83/EC)

This is a simplified procedure for products whose indications are appropriate to traditional herbal medicines. No clinical tests and trials on safety and efficacy are required, provided that sufficient safety data and plausible efficacy can be demonstrated. The product must have been used for at least 30 years, including at least 15 years within the EU, and it must be intended for use without the supervision of a medical practitioner and not administered by injection. Assessment relies mostly on bibliographic safety and efficacy data.

2. Well-established use marketing authorisation (Article 10a)

This pathway applies when scientific literature establishes that the active substances have been in well-established medicinal use within the EU for at least ten years, with recognised efficacy and an acceptable level of safety. As with traditional use registration, the assessment is based largely on published data rather than new clinical trials.

3. Stand-alone or mixed application (Article 8(3))

Where the conditions for the other pathways cannot be met, a company submits its own safety and efficacy data from development studies, or a combination of its own studies and bibliographic data. This is the most demanding route and is typically used for newer products without a long history of use.

Applications are submitted to the national competent authority of a member state for national, mutual recognition or decentralised procedures, or to the European Medicines Agency (EMA) where the centralised procedure applies.

A full quality dossier is always required

Regardless of the regulatory pathway chosen, a full quality dossier is required for all herbal medicinal products. Quality requirements are the same whether a product follows the traditional registration route or a marketing authorisation route. This is where botanical extract manufacturers play a decisive role, because the quality of the finished medicine starts with the quality of the extract.

Key quality requirements include:

• Active substance declaration: the drug extract ratio (DER) and the extraction solvent must be declared for extracts. The DER reflects the quantity of herbal substance used relative to the quantity of native extract obtained, and it is normally expressed as a range because of the natural variability of plant material.
• Testing and markers: analytical methods must allow the qualitative and quantitative determination of the active substances. Where constituents with known therapeutic activity are unknown, suitable analytical markers may be used instead.
• Contaminants: herbal substances must be controlled for mycotoxins such as aflatoxins and ochratoxin A, for microbiological quality, and for elemental impurities. A risk assessment determines the extent of testing required for each material.
• Manufacturing and stability: manufacturing must follow good manufacturing practice (GMP), and stability studies must demonstrate that the product maintains its quality throughout its shelf life.

Products should comply with the quality standards set out in the relevant European Pharmacopoeia (Ph. Eur.) monographs, or in their absence, those of a member state's pharmacopoeia.

HMPC monographs and the EU list

The EMA's Committee on Herbal Medicinal Products (HMPC) establishes EU monographs covering the therapeutic uses and safe conditions of herbal substances and preparations. It also drafts the EU list of herbal substances, preparations and combinations for use in traditional herbal medicinal products. If a company can demonstrate that its product complies with the EU list, no further evidence of safe and traditional use is required. These monographs give applicants and national authorities a clear, harmonised reference point and are increasingly used across all member states.

GMP, pharmacovigilance and labelling

Herbal medicinal products are subject to the same fundamental principles as all medicinal products: good manufacturing practice, pharmacovigilance, and requirements on packaging and labelling. Manufacturers of botanical extracts must therefore operate to GMP standards, maintain robust quality control systems, and provide the documentation needed to support pharmacovigilance obligations throughout the product's life cycle.

Import considerations for manufacturers outside the EU

For manufacturers outside the EU, such as those in China, additional import requirements apply. Consignments may be subject to increased official controls under Regulation (EU) 2019/1793, which can require pre-notification through the TRACES NT system via a Common Health Entry Document (CHED-D) addressed to the border control post of first entry. Contaminant limits under Regulation (EU) 2023/915, pesticide residue limits under Regulation (EC) 396/2005, and microbiological criteria under Regulation (EC) 2073/2005 all apply to botanical material entering the EU. Ethylene oxide is banned for food use in the EU, so microbial control must be achieved through validated alternatives such as steam treatment rather than fumigation.

How a reliable extract manufacturer supports compliance

Meeting these requirements is far easier when the botanical extracts themselves are produced to a high, consistent standard. Botaniex, a botanical extract manufacturer based in Changsha, China, builds regulatory readiness into every stage of production. Its science-driven R&D team, which includes PhDs, professors and researchers in phytochemistry, pharmacology and traditional Chinese medicine, develops standardized extracts with the documentation that pharmaceutical customers need. Advanced extraction techniques such as water, alcohol and supercritical CO₂ extraction allow precise control over active compound content, while quality control covers raw material authentication, in-process monitoring, active compound verification and microbial testing. This helps customers assemble the quality dossiers required for European market entry, whether they are sourcing single botanical extracts or developing proprietary herbal formulas for the dietary supplement, functional food and pharmaceutical industries.

Conclusion

The European regulatory framework for botanical extracts in pharmaceuticals is comprehensive, but it rewards well-prepared manufacturers. By understanding the three regulatory pathways, meeting the full quality dossier requirements, and working with a supplier that takes quality control seriously, companies can navigate the process with confidence. Whether you are developing a traditional herbal medicine or a well-established-use product, the key is to start with high-quality, well-documented botanical extracts — and to choose a manufacturing partner that understands what European regulators expect.